In 2011, Poirel et al. reported the first identification of NDM-1-producing isolates in the Arabian Peninsula and the Middle East. 22 Similar reports of Enterobacteriaceae harboring bla NDM-1 have also emerged from Kuwait and Lebanon. 23, 24 The recent identification of 11 NDM-1, five OXA-48, and one NDM-1 plus OXA-181 producers among carbapenem-resistant enterobacterial isolates from Oman, suggests that carbapenemase producers are now emerging in the region. 25 In Saudi Arabia, unpublished data suggest that carbapenem-resistant K. pneumoniae are being isolated in patients with serious nosocomial infections. We present the first report documenting the emergence of NDM-, OXA-48-, and VIM-producing K. pneumoniae in Saudi Arabia.
Methods
The study was carried out in Riyadh, Saudi Arabia, from June to December 2011. During the study period, all non-duplicate clinical and surveillance isolates of K. pneumoniae obtained from inpatients that showed reduced sensitivity to carbapenem were characterized.
Phenotypic detection of ESBLs and MBLs
ESBL screening was carried out by disk diffusion using ceftazidime (30 mg) and cefpodoxime (10 mg), in accordance with the recommendations of the Clinical and Laboratory Standards Institute (CLSI) guidelines. 26 Confirmation of ESBL phenotype was carried out using the ESBL Etest following the manufacturer's guidelines. Determination of the production of carbapenemase was carried out by modified Hodge test in accordance with the CLSI guidelines and Pasteran et al. 26, 27 Metallo-beta-lactamase (MBL) production was determined using Etest MBL strips (imipenem/ imipenem + ethylenediaminetetraacetic acid (EDTA)), in accordance with the manufacturer's directions. A 8-fold reduction in 
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Surgical ward Urine imipenem minimum inhibitory concentration (MIC) in the presence of EDTA, or a phantom zone, was taken as indicative of MBL production.
Detection of resistance genes
PCR amplification was carried out for the detection of bla ESBL (bla CTX-M , bla TEM , bla SHV ) with primers described previously. 28 PCR amplification was carried out for the detection of ESBL genes (bla CTX-M , bla TEM , bla SHV ) and carbapenemase genes (bla KPC , bla VIM , bla IMP , bla SIM , bla GIM , bla SPM , bla NDM , and bla OXA-48 ) using previously described primers and methodology. [29] [30] [31] [32] The subgroups of CTX-M were determined by PCR using the procedures of Woodford et al. 33 
Antibiotic susceptibility
MICs of imipenem and meropenem were determined by Etest, as described previously, in accordance with CLSI guidelines. 26 Sensitivity to a panel of antibiotics including amikacin, gentamicin, trimethoprim-sulfamethoxazole, and colistin, was assessed.
Results
A total of 60 K. pneumoniae isolates were identified and studied. The majority of these were from patients in the intensive care unit (ICU; n = 45), while others were from patients on the surgical and medical wards. Specimen sources were blood (n = 9), rectal swabs (n = 16), sputum (n = 13), urine (n = 11), wound (n = 9), and suction swab (n = 2). All isolates were confirmed to be carbapenemaseproducers by modified Hodge test. The carbapenemase gene bla OXA-48 was detected in 47 (78%) isolates, bla NDM-1 in 12 (20%), and bla VIM in one (1.6%). No isolate harbored a combination of bla NDM-1 and bla OXA-48 . None of the isolates harbored either bla KPC or bla IMP . Thirty-seven isolates were positive for bla CTX-M and all belonged to CTX-M group 1. Twenty-nine were positive for both bla CTX-M and bla OXA-48 . The bla TEM and bla SHV genes were detected in 17 and 39 isolates, respectively. All isolates were resistant to imipenem and meropenem. The distribution, characterization, and antibiotic susceptibility profile of bla OXA-48 -positive and bla NDM-1 -positive isolates are shown in Tables 1 and 2 , respectively. There was a high degree of resistance to amikacin, gentamicin, ciprofloxacin, and trimethoprim-sulfamethoxazole. Three isolates with resistance to colistin were identified and they were positive for bla (Table 1) .
Discussion
The dissemination of K. pneumoniae isolates harboring carbapenemase resistance genes, in particular bla OXA-48 and bla NDM-1 , continues unabated, and reports describing these isolates are emerging from different parts of the world. In the Arabian Gulf region, NDM-1, OXA-48, and OXA-181 carbapenemase-producing Enterobacteriaceae have been reported in Oman. 22 In addition, the detection of bla NDM-1 -positive K. pneumoniae in two patients at a tertiary care teaching hospital in Kuwait has been reported. 24 A PubMed search did not identify any published report describing the occurrence and distribution of bla OXA-48 -and bla NDM-1 -producing Enterobacteriaceae in Saudi Arabia. The data presented here, based on a 6-month survey, provide the first insight into the widespread occurrence of K. pneumoniae isolates harboring bla OXA-48 and bla NDM-1 among patients in healthcare facilities in Riyadh, Saudi Arabia. The majority of the isolates were from clinical specimens and were from patients in the ICU. This indicates that in this setting K. pneumoniae isolates producing carbapenemases are associated with nosocomial infections in seriously ill patients. Although India and Pakistan are considered to be the main reservoir for NDM-producing isolates, it has been suggested that the Middle East region might be a secondary reservoir for the spread of bla NDM-1 isolates as there is a high frequency of population movement between Saudi Arabia and the Indian subcontinent. 34, 35 We speculate that a similar population movement with Turkey, where K. pneumoniae with bla OXA-48 is endemic, might explain the high occurrence of isolates with this resistance gene in our setting, although the absence of data on travel history for the patients precludes any firm conclusions being drawn. The emergence of bla NDM-1 and bla OXA-48 isolates in our setting has significant implications as it is not uncommon for patients from Saudi Arabia to travel abroad for further healthcare services, raising the possibility of dissemination of these isolates into other countries. Indeed, such dissemination via health tourism was demonstrated in a recently published report of the first two clinical cases of OXA-48-type carbapenemase-producing Enterobacteriaceae in the USA, in which one of the patients had a history of recent hospitalization in Saudi Arabia. 36 Only one isolate was found with bla VIM and no KPC isolates were identified, indicating that these are not major sources of carbapenemases in our setting. The plasmid-encoded KPC enzyme was first identified in a K. pneumoniae isolate from North Carolina, USA. 37 Since 2001, these isolates have spread across the USA, with reports of KPC-producers across 38 states. 37, 38 Although 
Surgical ward Urine bla CTX-M ; bla SHV R R R R S Total bla CTX-M = 8 bla SHV = 7 bla TEM = 2 R = 11 R = 11 R = 10 R = 12 R = 0 KPC-producers are now being identified at an alarming rate across Europe, facilitated mostly by clonal dissemination, to the best of our knowledge there is no published report of bla KPC -positive isolates from the Arabian Peninsula. 39 The antibiotic susceptibility profile of our isolates is in keeping with the reported multidrug-resistant phenotype associated with isolates harboring bla NDM-1 and bla OXA-48 . The weak hydrolytic effect on carbapenems exhibited by OXA-48-producers is not affected by EDTA or clavulanic acid, but is enhanced if there is associated ESBL activity and outer membrane permeability defects.
14 Thus the co-existence of beta-lactamase genes such as demonstrated in our isolates, enhances the antimicrobial resistance, particularly in bla OXA-48 isolates. As colistin remains one of the last drugs of choice for the treatment of infections caused by carbapenemase-producing Enterobacteriaceae, the finding of carbapenemase-producers with resistance to this, as reported herein, is of major concern. Although this report has documented the widespread occurrence of these isolates in our setting, a major limitation is the absence of detailed epidemiological data and molecular characterization. Hence, we suggest that there is an urgent need for further studies to clearly map out the epidemiology and to conduct molecular characterization of carbapenemaseproducing isolates in Saudi Arabia. Healthcare facilities in the country need to be aware of the emergence of these multidrugresistant isolates, as these are of significant public health concern both in the hospital and community setting. A process of enhanced surveillance for the detection of these multidrug-resistant pathogens is urgently advocated so that patients can be identified quickly and appropriate infection control measures instituted to stem further dissemination.
